D.E. Shaw & Co
AMPH icon

D.E. Shaw & Co’s Amphastar Pharmaceuticals AMPH Stock Holding History

D.E. Shaw & Co’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13M Buy
665,542
+108,476
+19% +$2.65M 0.01% 1419
2025
Q4 		$14.9M Buy
557,066
+39,844
+8% +$1.03M 0.01% 1439
2025
Q3 		$13.8M Buy
517,222
+223,294
+76% +$5.77M 0.01% 1431
2025
Q2 		$6.75M Buy
293,928
+264,740
+907% +$6.57M ﹤0.01% 1797
2025
Q1 		$846K Sell
29,188
-89,663
-75% -$2.86M ﹤0.01% 3195
2024
Q4 		$4.41M Buy
118,851
+95,192
+402% +$4.35M ﹤0.01% 2082
2024
Q3 		$1.15M Buy
+23,659
New +$1.04M ﹤0.01% 3177
2024
Q1 		– Sell
-77,080
Closed -$4.77M – 4316
2023
Q4 		$4.77M Sell
77,080
-23,093
-23% -$1.21M ﹤0.01% 1944
2023
Q3 		$4.61M Sell
100,173
-23,426
-19% -$1.28M ﹤0.01% 1881
2023
Q2 		$7.1M Sell
123,599
-13,714
-10% -$608K 0.01% 1623
2023
Q1 		$5.15M Buy
137,313
+79,365
+137% +$2.6M 0.01% 1917
2022
Q4 		$1.62M Buy
57,948
+69
+0.1% +$2K ﹤0.01% 3097
2022
Q3 		$1.63M Sell
57,879
-3,856
-6% -$126K ﹤0.01% 3182
2022
Q2 		$2.15M Sell
61,735
-3,404
-5% -$121K ﹤0.01% 3001
2022
Q1 		$2.34M Buy
65,139
+38,370
+143% +$1.09M ﹤0.01% 3156
2021
Q4 		$623K Buy
+26,769
New +$547K ﹤0.01% 4276
2021
Q3 		– Sell
-35,699
Closed -$720K – 4938
2021
Q2 		$720K Buy
35,699
+17,921
+101% +$338K ﹤0.01% 3810
2021
Q1 		$326K Buy
17,778
+4,891
+38% +$90.9K ﹤0.01% 3675
2020
Q4 		$259K Buy
+12,887
New +$251K ﹤0.01% 3645
2016
Q3 		– Sell
-14,208
Closed -$229K – 3355
2016
Q2 		$229K Sell
14,208
-8,293
-37% -$117K ﹤0.01% 3142
2016
Q1 		$270K Sell
22,501
-78,974
-78% -$931K ﹤0.01% 3065
2015
Q4 		$1.44M Buy
101,475
+84,153
+486% +$1.11M ﹤0.01% 2381
2015
Q3 		$202K Sell
17,322
-14,110
-45% -$212K ﹤0.01% 3498
2015
Q2 		$553K Sell
31,432
-4,470
-12% -$69.7K ﹤0.01% 3106
2015
Q1 		$537K Buy
+35,902
New +$480K ﹤0.01% 3015

Other funds holding AMPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

D.E. Shaw & Co's AMPH Position: Q1 2026 in Review

D.E. Shaw & Co increased its Amphastar Pharmaceuticals (AMPH) stake by 19% in Q1 2026, buying an estimated $2.65M and bringing the position to 665,542 shares worth $13M. The position accounts for 0.01% of the portfolio, ranked #1419.

D.E. Shaw & Co first reported a position in AMPH in Q1 2015 and has held it in 25 quarters since. The position peaked at $14.9M in Q4 2025. 215 funds tracked by Wall St. Rank hold AMPH as of Q1 2026.

  • D.E. Shaw & Co held 665,542 shares of Amphastar Pharmaceuticals worth $13M as of Q1 2026.
  • D.E. Shaw & Co bought 108,476 Amphastar Pharmaceuticals shares in Q1 2026, an estimated $2.65M.
  • Amphastar Pharmaceuticals made up 0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1419 holding.
  • D.E. Shaw & Co first reported a position in Amphastar Pharmaceuticals in Q1 2015 and has held it in 25 quarters since.
  • D.E. Shaw & Co's Amphastar Pharmaceuticals position peaked at $14.9M in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.